Figure 11.

MONs for drug delivery. a) The nanostructure and composition of mesoporous organosilica nanoparticles. After mixing with DOX for local administration, the nanoreactors are able to i) amplify ICD, ii) act as immune adjuvants to stimulate the maturation of immune cells. Reproduced with permission.^{[ 175 ]} Copyright 2018, Wiley‐VCH. b) Illustration of the DDMON–IONP–CUR ICD nanoinducer for cancer immunotherapy. Reproduced with permission.^{[ 176 ]} Copyright 2020, American Chemical Society. c) Schematic of synthesis of diselenide‐bond‐bridged MONs for low‐dose X‐ray‐radiation‐controllable drug release. Reproduced with permission.^{[ 180 ]} Copyright 2020, Wiley‐VCH. d) DOX@PMO–hT (HA5ST modified with three amino acids Pro‐Lys‐Cys at the C‐terminus, hT) synthesis and antitumor mechanisms. Reproduced with permission.^{[ 181 ]} Copyright 2022, Elsevier.